Nothing Special   »   [go: up one dir, main page]

DK588487A - Forbedrede metalholdige farmaceutiske midler - Google Patents

Forbedrede metalholdige farmaceutiske midler

Info

Publication number
DK588487A
DK588487A DK588487A DK588487A DK588487A DK 588487 A DK588487 A DK 588487A DK 588487 A DK588487 A DK 588487A DK 588487 A DK588487 A DK 588487A DK 588487 A DK588487 A DK 588487A
Authority
DK
Denmark
Prior art keywords
pharmaceutical agents
metal containing
containing pharmaceutical
improved metal
improved
Prior art date
Application number
DK588487A
Other languages
English (en)
Other versions
DK168728B1 (da
DK588487D0 (da
Inventor
Heinz Gries
Ulrich Speck
Hanns-Joachim Weinmann
Hans Peter Niendorf
Wolfgang Seifert
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6315011&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK588487(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of DK588487D0 publication Critical patent/DK588487D0/da
Publication of DK588487A publication Critical patent/DK588487A/da
Application granted granted Critical
Publication of DK168728B1 publication Critical patent/DK168728B1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6887—Antibody-chelate conjugates using chelates for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/90—In vivo diagnostic or in vivo test agent which contains an additional ingredient to reduce the toxicity or side effects of the active ingredient
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
DK588487A 1986-11-28 1987-11-10 Anvendelse af en eller flere kompleksdannere og/eller et eller flere svagere metalkomplekser eller blandinger heraf som additiv ved fremstilling af farmaceutiske midler til NMR-diagnostik DK168728B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3640708 1986-11-28
DE3640708A DE3640708C2 (de) 1986-11-28 1986-11-28 Verbesserte metallhaltige Pharmazeutika

Publications (3)

Publication Number Publication Date
DK588487D0 DK588487D0 (da) 1987-11-10
DK588487A true DK588487A (da) 1988-05-29
DK168728B1 DK168728B1 (da) 1994-05-30

Family

ID=6315011

Family Applications (1)

Application Number Title Priority Date Filing Date
DK588487A DK168728B1 (da) 1986-11-28 1987-11-10 Anvendelse af en eller flere kompleksdannere og/eller et eller flere svagere metalkomplekser eller blandinger heraf som additiv ved fremstilling af farmaceutiske midler til NMR-diagnostik

Country Status (16)

Country Link
US (4) US5098692A (da)
EP (1) EP0270483B2 (da)
JP (1) JPH0662444B2 (da)
AT (1) ATE78705T1 (da)
AU (1) AU607727B2 (da)
CA (1) CA1322156C (da)
DE (2) DE3640708C2 (da)
DK (1) DK168728B1 (da)
ES (1) ES2051768T5 (da)
GR (2) GR3005319T3 (da)
IE (1) IE61663B1 (da)
IL (1) IL84598A (da)
NO (1) NO173976C (da)
NZ (1) NZ222677A (da)
PT (1) PT86224B (da)
ZA (1) ZA878952B (da)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219553A (en) * 1986-08-04 1993-06-15 Salutar, Inc. Composition of a n-carboxymethylated tetraazacyclododecane chelating agent, a paramagnetic metal and excess calcium ions for MRI
US5039512A (en) * 1986-08-04 1991-08-13 Salutar, Inc. NMR imaging with paramagnetic polyvalent metal salts of poly-(acid-alkylene-amino)-alkanes
DE3640708C2 (de) * 1986-11-28 1995-05-18 Schering Ag Verbesserte metallhaltige Pharmazeutika
US5399340A (en) * 1987-09-24 1995-03-21 Schering Aktiengesellschaft Use of amide complex compounds
US5137711A (en) † 1988-07-19 1992-08-11 Mallickrodt Medical, Inc. Paramagnetic dtpa and edta alkoxyalkylamide complexes as mri agents
US5314681A (en) * 1988-12-23 1994-05-24 Nycomed Innovation Ab Composition of positive and negative contrast agents for electron spin resonance enhanced magnetic resonance imaging
GB8900719D0 (en) * 1989-01-13 1989-03-08 Nycomed As Compounds
US5364613A (en) * 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US5087440A (en) * 1989-07-31 1992-02-11 Salutar, Inc. Heterocyclic derivatives of DTPA used for magnetic resonance imaging
DE4011684A1 (de) * 1990-04-06 1991-10-10 Schering Ag Dtpa-monoamide, diese verbindungen enthaltende pharmazeutische mittel, ihre verwendung und verfahren zu deren herstellung
US5843399A (en) * 1990-04-06 1998-12-01 Schering Aktiengesellschaft DTPA monoamides for MRI
US5368840A (en) * 1990-04-10 1994-11-29 Imarx Pharmaceutical Corp. Natural polymers as contrast media for magnetic resonance imaging
CA2039399C (en) * 1990-04-25 2000-09-05 C. Allen Chang Dual functioning excipient for metal chelate contrast agents
US5439913A (en) 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
US5807535A (en) * 1992-07-31 1998-09-15 Australian Nuclear Science & Technology Organisation Metal complexes of hydroxyaryl containing aminocarboxylic acid chelating agents
EP0590766B1 (en) * 1992-07-31 2000-02-02 Australian Nuclear Science And Technology Organisation Hydroxylaryl containing aminocarboxylic acid chelating agents
US5346997A (en) * 1992-08-26 1994-09-13 Murphy James G Agents for complexing sodium under biological conditions
DE19543077C2 (de) * 1995-11-13 1997-10-16 Schering Ag Verwendung von gashaltigen Metallkomplexen als Ultraschallkontrastmittel
US5834513A (en) * 1996-04-25 1998-11-10 Avon Products, Inc. Oxa diacids and related compounds for treating skin conditions
US5932229A (en) * 1996-04-25 1999-08-03 Avon Products, Inc. Oxa diacids and related compounds for treating skin conditions
US5847003A (en) * 1996-06-04 1998-12-08 Avon Products, Inc. Oxa acids and related compounds for treating skin conditions
US6896874B2 (en) * 1998-05-26 2005-05-24 Wisconsin Alumni Research Foundation MR-signal emitting coatings
US6361759B1 (en) 1998-05-26 2002-03-26 Wisconsin Alumni Research Foundation MR signal-emitting coatings
EP1180055A2 (de) * 1999-05-12 2002-02-20 Laser- und Medizin-Technologie GmbH Berlin Anordnung zur strahlentherapie
US20030203879A1 (en) * 1999-09-09 2003-10-30 Schering Ag Calcium complex of [[(4R)-4-[bis[(carboxy-.kappa.O)methyl]amino-.kappa.n]-6,9-bis[(carboxy.kappa.O)methyl]-1-[(4,4-diphenylcyclohexy)oxy]-1-hydroxy-2-oxa-6,9-diaza-1-phosphaundecan-11-ylic-acid-.kappa.N6,.Kappa.N9,.Kappa 011]1-oxidato(6-)]-, hexahydrogen, its salts, pharmaceutical agents that contain these complexes, their use in treatment and as additives in diagnosis, as well as processes for the production of the complexes and agents
US6559330B1 (en) 1999-09-09 2003-05-06 Schering Aktiengesellschaft Calcium complex of [[(4r)-4-[bis{carboxy-.kappa.o)methyl]amino-.kappa.n]-6,9-bis[(carboxy.kappa.o)methyl]-1-[(4,4-diphenylcyclohexyl)oxy]-1-hydroxy-2-oxa-6,9-diaza-1-phosphaundecan-11-ylic-acid-.kappa.n6,.kappa.n9,.kappa.011]1-oxidato(6-)]-, hexahydrogen, its salts, pharmaceutical agents that contain these complexes, their use in treatment and as additives in diagnosis, as well as processes for the production of the complexes and agents
US7189705B2 (en) 2000-04-20 2007-03-13 The University Of British Columbia Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
US20040258620A1 (en) * 2001-06-22 2004-12-23 Lutz Lehmann (Ethylene)-( propylene)-triaminepentaacetic acid derivatives, process for their production, and their use for the production of pharmaceutical agents
WO2004006934A2 (de) * 2002-07-10 2004-01-22 Hans Robert Kalbitzer 1,4,7,10-tetraazacyclododecane als modulatoren des guanin-nukleotid bindenden roteins zur behandlung von tumoren
US20040253292A1 (en) * 2003-04-23 2004-12-16 Wisconsin Alumni Research Foundation MR-signal emitting coatings
US8457712B2 (en) * 2005-12-30 2013-06-04 Wisconsin Alumni Research Foundation Multi-mode medical device system and methods of manufacturing and using same
US20070156042A1 (en) * 2005-12-30 2007-07-05 Orhan Unal Medical device system and method for tracking and visualizing a medical device system under MR guidance
CA2646424C (en) * 2006-03-17 2015-12-29 Johnson & Johnson Vision Care, Inc. Methods for stabilizing oxidatively unstable compositions
US8532742B2 (en) * 2006-11-15 2013-09-10 Wisconsin Alumni Research Foundation System and method for simultaneous 3DPR device tracking and imaging under MR-guidance for therapeutic endovascular interventions
US20080183070A1 (en) * 2007-01-29 2008-07-31 Wisconsin Alumni Research Foundation Multi-mode medical device system with thermal ablation capability and methods of using same
US8412306B2 (en) * 2007-02-28 2013-04-02 Wisconsin Alumni Research Foundation Voltage standing wave suppression for MR-guided therapeutic interventions
US8147802B2 (en) * 2007-09-28 2012-04-03 General Electric Company Chelator-functionalized nanoparticles
FR2927539B1 (fr) * 2008-02-19 2010-07-30 Guerbet Sa Procede de preparation d'une formulation pharmaceutique d'agents de contraste.
US20090208421A1 (en) * 2008-02-19 2009-08-20 Dominique Meyer Process for preparing a pharmaceutical formulation of contrast agents
FR2945448B1 (fr) * 2009-05-13 2012-08-31 Guerbet Sa Procede de preparation d'une formulation pharmaceutique de chelate de lanthanide sous forme de poudre.
DE102009053171B4 (de) 2009-11-04 2011-07-21 Bayer Schering Pharma Aktiengesellschaft, 13353 Verfahren zur Herstellung des Calcium-Komplexes von Dihydroxy-hydroxy-methylpropyl-tetraazacyclododecan-triessigsäure (Calcobutrol)
NO331773B1 (no) 2009-12-18 2012-03-26 Ge Healthcare As Mangankelater, sammensetninger omfattende slike og anvendelse av disse som kontrastmidler for magnettomografi (MR)
DE102010023890A1 (de) 2010-06-11 2011-12-15 Bayer Schering Pharma Aktiengesellschaft Verfahren zur Herstellung kristalliner 3,6,9-Triaza-3,6,9-tris(carboxymethyl)-4-(ethoxybenzyl)-undecandinsäure und die Verwendung zur Herstellung von Primovist
MA34304B1 (fr) 2010-06-11 2013-06-01 Bayer Ip Gmbh Procédé de préparation d'acide 3,6,9-triaza-3,6,9-tris(carboxyméthyl)-4-(4-éthoxybenzyl)-undécandioïque cristallin et son utilisation pour la préparation de primovist®
WO2012136813A2 (en) 2011-04-07 2012-10-11 Universitetet I Oslo Agents for medical radar diagnosis
CU24439B1 (es) 2011-04-21 2019-09-04 Bayer Ip Gmbh Preparación de gadobutrol de alta pureza
EP2786768A1 (en) 2013-04-04 2014-10-08 Agfa Healthcare Process for preparing a material comprising a macrocyclic ligand and for producing a pharmaceutical formulation comprising said ligand with a lanthanide
HRP20170874T4 (hr) 2013-04-26 2022-09-02 Guerbet Formulacija kontrastnog medija i odgovarajući postupak dobivanja
AT516104B1 (de) 2014-07-31 2016-08-15 Sanochemia Pharmazeutika Ag Verfahren zum Herstellen einer flüssigen pharmazeutischen Zubereitung
GB201421162D0 (en) 2014-11-28 2015-01-14 Ge Healthcare As Lanthanide complex formulations
DE102015013939A1 (de) 2015-09-15 2017-03-16 be imaging GmbH Verfahren zur Herstellung von Gadotersäure (Gd-DOTA)- Komplexen
GB201610738D0 (en) 2016-06-20 2016-08-03 Ge Healthcare As Chelate compounds
JP7053590B2 (ja) 2016-09-27 2022-04-12 バイエル・ファルマ・アクティエンゲゼルシャフト カルコブトロールの変態ａの結晶形態を製造する方法
WO2018069179A1 (en) 2016-10-12 2018-04-19 T2Pharma Gmbh Method of preparing formulations of lanthanide metal complexes of macrocyclic chelates
WO2018069176A1 (en) 2016-10-12 2018-04-19 T2Pharma Gmbh Method of preparing formulations of lanthanide metal complexes of macrocyclic chelates
JP7034160B2 (ja) 2016-11-28 2022-03-11 バイエル・ファルマ・アクティエンゲゼルシャフト 磁気共鳴画像法に使用するための高緩和度ガドリニウムキレート化合物
ES2813077T3 (es) 2016-12-21 2021-03-22 Ge Healthcare As Compuestos quelatos de manganeso basados en macrociclo de tetraazabiciclo adecuados como agentes de imagen de IRM
EP3728168B1 (en) 2017-12-20 2022-03-30 General Electric Company Anionic chelate compounds
AT521001B1 (de) * 2018-02-23 2020-10-15 Sanochemia Pharmazeutika Ag Herstellungsverfahren für ein Kontrastmittel
US11944690B2 (en) * 2018-11-23 2024-04-02 Bayer Aktiengesellschaft Formulation of contrast media and process of preparation thereof
FR3091873B1 (fr) 2019-01-17 2020-12-25 Guerbet Sa Complexe de gadolinium et d’un ligand chelateur derive de pcta diastereoisomeriquement enrichi et procede de preparation et de purification
EP4077271A1 (en) 2019-12-20 2022-10-26 Bracco Imaging SPA Calcium bopta complex
GB201919073D0 (en) 2019-12-20 2020-02-05 Ge Healthcare As Novel manufacturing process
KR20230041007A (ko) 2020-07-17 2023-03-23 게르브 Pcta로부터 유도된 킬레이팅 리간드의 제조 방법

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB736432A (en) * 1952-01-16 1955-09-07 Dow Chemical Co Improvements in or relating to compositions for the x-ray visualization of the organs and cavities of the body
US3033757A (en) * 1959-04-08 1962-05-08 Mallinckrodt Chemical Works X-ray contrast agents
US3175952A (en) * 1963-05-29 1965-03-30 Sterling Drug Inc Aqueous radiopaque solutions containing sodium and calcium ions
US3633688A (en) * 1970-02-13 1972-01-11 Albert G Bodine Torsional rectifier drilling device
US4247534A (en) * 1978-07-31 1981-01-27 The Procter & Gamble Company Radiographic scanning agent
US4432963A (en) * 1978-07-31 1984-02-21 Mallinckrodt, Inc. Radiographic scanning agent
DE2943498C2 (de) * 1979-10-27 1983-01-27 Henkel KGaA, 4000 Düsseldorf Verfahren zur Herstellung von 3-Amino-1-hydroxypropan-1,1-diphosphonsäure
CA1178951A (en) * 1980-03-18 1984-12-04 Claude F. Meares Chelating agents and method
DE3129906C3 (de) * 1981-07-24 1996-12-19 Schering Ag Paramagnetische Komplexsalze, deren Herstellung und Mittel zur Verwendung bei der NMR-Diagnostik
US4957939A (en) * 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4647447A (en) * 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4478816A (en) * 1982-06-07 1984-10-23 Georgetown University Rare earth/chelating agent complex for digital fluoroscopy
NL194579C (nl) * 1983-01-21 2002-08-05 Schering Ag Diagnostisch middel.
DE3324235A1 (de) * 1983-07-01 1985-01-10 Schering AG, 1000 Berlin und 4709 Bergkamen Neue komplexbildner, komplexe und komplexsalze
GB8413772D0 (en) * 1984-05-30 1984-07-04 Nyegaard & Co As Chemical compounds
US4749560A (en) * 1984-08-13 1988-06-07 Research Corporation Metal organo phosphorous compounds for NMR analysis
SE465907B (sv) * 1984-11-01 1991-11-18 Nyegaard & Co As Diagnosticeringsmedel innehaallande en paramagnetisk metall
US5082649A (en) * 1987-06-30 1992-01-21 Mallinckrodt Medical, Inc. Method for enhancing the safety of metal-ligand chelates as magnetic resonance imaging agents by addition of calcium ions
US4826673A (en) * 1985-01-09 1989-05-02 Mallinckrodt, Inc. Methods and compositions for enhancing magnetic resonance imaging
US4980148A (en) * 1985-02-06 1990-12-25 Mallinckrodt, Inc. Methods for enhancing magnetic resonance imaging
US4746507A (en) * 1985-04-02 1988-05-24 Salutar, Inc. EDHPA based contrast agents for MR imaging, apparatus and methods
US5039512A (en) * 1986-08-04 1991-08-13 Salutar, Inc. NMR imaging with paramagnetic polyvalent metal salts of poly-(acid-alkylene-amino)-alkanes
US5219553A (en) * 1986-08-04 1993-06-15 Salutar, Inc. Composition of a n-carboxymethylated tetraazacyclododecane chelating agent, a paramagnetic metal and excess calcium ions for MRI
IL83966A (en) * 1986-09-26 1992-03-29 Schering Ag Amides of aminopolycarboxylic acids and pharmaceutical compositions containing them
DE3640708C2 (de) * 1986-11-28 1995-05-18 Schering Ag Verbesserte metallhaltige Pharmazeutika
IE66694B1 (en) * 1988-09-27 1996-01-24 Nycomed Salutar Inc Chelate compositions
US5078986A (en) * 1989-02-15 1992-01-07 Mallinckrodt Medical, Inc. Method for enhancing magnetic resonance imaging using an image altering agent containing an excess of chelating agent
JPH04311288A (ja) * 1991-04-09 1992-11-04 Daido Denki Kogyo Kk 通行者数検出装置
JPH09311288A (ja) * 1996-05-16 1997-12-02 Ricoh Co Ltd 光走査装置

Also Published As

Publication number Publication date
EP0270483B1 (de) 1992-07-29
PT86224A (de) 1987-12-01
JPS63145239A (ja) 1988-06-17
IE873222L (en) 1988-05-28
NO173976B (no) 1993-11-22
DK168728B1 (da) 1994-05-30
ES2051768T3 (es) 1994-07-01
CA1322156C (en) 1993-09-14
US20060165591A1 (en) 2006-07-27
IL84598A0 (en) 1988-04-29
DE3780776D1 (de) 1992-09-03
NO173976C (no) 1994-03-02
ES2051768T5 (es) 1996-06-16
US20030206858A1 (en) 2003-11-06
PT86224B (pt) 1990-11-07
EP0270483A3 (en) 1989-12-27
US5876695A (en) 1999-03-02
DK588487D0 (da) 1987-11-10
EP0270483B2 (de) 1996-02-14
NZ222677A (en) 1990-07-26
NO874971L (no) 1988-05-30
GR3019002T3 (en) 1996-05-31
DE3640708C2 (de) 1995-05-18
IL84598A (en) 1991-01-31
GR3005319T3 (en) 1993-05-24
AU8188987A (en) 1988-06-02
ATE78705T1 (de) 1992-08-15
IE61663B1 (en) 1994-11-16
US5098692A (en) 1992-03-24
AU607727B2 (en) 1991-03-14
ZA878952B (en) 1988-07-27
EP0270483A2 (de) 1988-06-08
DE3640708A1 (de) 1988-06-09
NO874971D0 (no) 1987-11-27
JPH0662444B2 (ja) 1994-08-17

Similar Documents

Publication Publication Date Title
DK588487D0 (da) Forbedrede metalholdige farmaceutiske midler
DE3776320D1 (de) Pulverfoermiges haarfaerbemittel.
BG95935A (bg) Метод и средство за приемане на дексмедетомидин директно през кожата
MX9203176A (es) 1,2,4-triazolonas substituidas con fenoxietilo y composiciones farmaceuticas que las contienen.
DE3860989D1 (de) Amin-mischungshilfsmittel in schmieroelgemischen.
BR8901723A (pt) Composicao de limpeza liquida,aquosa,homogenea e limpida
MX9203099A (es) N-heterociclico-n-(4-piperidia)amidas y composiciones farmaceuticas y metodos que emplean dichos compuestos.
EP0055300A4 (en) PLATINUM COMPLEXES (II) AND ANTINEOPLASTIC AGENTS CONTAINING THEM, USED AS EFFECTIVE COMPONENTS.
IT8721410A0 (it) Composizione farmaceutica idrosolubile contenente n acetilcisteina.
DE3579730D1 (de) Eisen-3-hydroxypyron- oder 3-hydroxypyridon-komplexe und diese enthaltende pharmazeutische zusammensetzungen.
SE8002831L (sv) Oxitetracyklinberedningar
DE3878774D1 (de) Paraherquamid und dihydroparaherquamid als antiparasitaere mittel.
JPS5251755A (en) Agents for treating excreta
BE883748A (fr) Beta-octamolybdate de didodecylammonium et compositions le contenant
DK293488A (da) Fortykningsmiddel til tixotrope belaegningsmasser
DK24687D0 (da) 3-alkoxyflavonderivater samt antiviralt virksomme terapeutiske midler indeholdende disse
DK330687D0 (da) Forbindelser og farmaceutiske kompositioner, der er anvendelige som cardiotoniske midler
DE3883972D1 (de) Halterung von Gerüsteinsteckteilen.
DE3782799D1 (de) Fluessigmetall-ionenquelle und -legierung.
DE69015732D1 (de) Flüssigkristallzusammensetzung und dieselbe enthaltende Vorrichtung.
DE58908686D1 (de) Lederbehandlungsmittel.
NO900731D0 (no) Boelgelengde-spesifikke cytotoksiske midler.
IT8919077A0 (it) Composizione farmaceutica contenente nac e suo impiego.
IT8125957A0 (it) Derivato 2-aminotiazolico e composizione medicinale contenente lo stesso.
NO167657C (no) Gem-dihalo-1,8-diamino-4-aza-octanderivater, og diagnostiske midler inneholdende disse.

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PUP Patent expired